Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07023666 · ClinicalTrials.gov registry record · Phase 2
Early Screening and Treatment of Heart Complication in Sickle Cell Disease
A Phase 2 study of Sickle Cell Disease, sponsored by Inova Health Care Services.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 100
- Enrollment target
- 2
- Study locations
NCT07023666: Recruiting Phase 2 study of Sickle Cell Disease, sponsored by Inova Health Care Services.
NCT07023666 is a Phase 2 study of Sickle Cell Disease that is actively recruiting participants, run by Inova Health Care Services. The registered enrollment target is 100 participants, below the 292-participant average among 213 other Sickle Cell Disease trials with a reported enrollment target (66% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07023666, a Phase 2 study of Sickle Cell Disease, is actively recruiting participants, sponsored by Inova Health Care Services.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 100 participants
- Enrollment target
- 2
- Study locations
Study Summary
This study tests whether early heart screening and treatment for iron overload in subjects with sickle cell disease can prevent heart problems and reduce hospitalizations.
Primary Outcome
Total number of participants hospitalized for SCD related complications including vaso-occlusive crises, acute chest syndrome and infection detect the impact of early intervention of cardiac iron overload in patients with Sickle Cell Disease
Conditions Studied
Interventions
- DRUG Deferoxamine
- DRUG Deferasirox
- DRUG Deferiprone
- DEVICE Echocardiography
- DEVICE Electrocardiogram (ECG)
Study Locations (2)
Virginia
- Inova Schar Cancer - Fairfax
- Inova Health Care Service - Falls Church
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2025-10-07 |
| Est. Completion | 2027-06-30 |
| Phase | Phase 2 |
What NCT07023666 shows while recruiting
NCT07023666 is an interventional study that assigns participants to a tested intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap, below the 292-participant average among 213 other Sickle Cell Disease trials with a reported enrollment target (66% lower).
The record links to 1 condition, with Sickle Cell Disease appearing as the primary indexed condition, and to 5 interventions - of which Deferoxamine is the first listed.
NCT07023666 reports a single indexed study location in Virginia.
Frequently Asked Questions
What is clinical trial NCT07023666 about?
NCT07023666 is a clinical study titled "Early Screening and Treatment of Heart Complication in Sickle Cell Disease". This study tests whether early heart screening and treatment for iron overload in subjects with sickle cell disease can prevent heart problems and reduce hospitalizations.
What is the current status of trial NCT07023666?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 100 participants. The study started on 2025-10-07. Estimated completion is 2027-06-30.
What conditions does trial NCT07023666 study?
This clinical trial studies the following conditions: Sickle Cell Disease.
What interventions are being tested in trial NCT07023666?
The interventions under investigation include: Deferoxamine (DRUG), Deferasirox (DRUG), Deferiprone (DRUG), Echocardiography (DEVICE), Electrocardiogram (ECG) (DEVICE).
Who is sponsoring clinical trial NCT07023666?
This trial is sponsored by Inova Health Care Services, which has 75 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07023666 being conducted?
This trial has 2 study locations across Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Sickle Cell Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07023666's enrollment target sits among peer trials
100 60th of 213 higher than 150 of 213 other Sickle Cell Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Sickle Cell Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Sub-dissociative Dose Ketamine in Treatment of Vaso-occlusive Pain Event in Children and Young Adults
RECRUITING · Phase 2
-
Relationship Between Abnormal Myocardial Perfusion and Diastolic Dysfunction in Sickle Cell Disease Using PET
RECRUITING · Phase 2
-
Myeloablative Conditioning, Prophylactic Defibrotide and Haplo AlloSCT for Patients With Sickle Cell Disease
RECRUITING · Phase 2
-
A Study of Immune Suppression Treatment for People With Sickle Cell Disease or β-Thalassemia Who Are Going to Receive an Allogeneic Hematopoietic Cell Transplantation (HCT)
RECRUITING · Phase 2
-
A Phase 2/3 Study in Adult and Adolescent Participants With SCD
RECRUITING · Phase 2
-
Allo HSCT for High Risk Hemoglobinopathies
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01048281 · 100 participants
Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma
- NCT01161199 · 100 participants
The Use of Leukapheresis to Support HIV Pathogenesis Studies
- NCT01327690 · 100 participants · Early Phase 1
Mental Health in Veterans and Families After Group Therapies
- NCT01730781 · 100 participants
Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI